Cancer patients get continued access to promising drug in rollover study
NCT ID NCT05629234
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study offers continued treatment with the drug osimertinib to cancer patients who were already benefiting from it in a previous clinical trial. The goal is to keep providing the drug while monitoring for serious side effects. About 37 participants are enrolled, and the study is no longer recruiting new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Taoyuan, 333, Taiwan
-
Research Site
Nottingham, NG5 1PB, United Kingdom
-
Research Site
Seoul, 5505, South Korea
-
Research Site
Kaohsiung City, 83301, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Tainan, 736, Taiwan
-
Research Site
Taipei, 112201, Taiwan
-
Research Site
Beijing, 100142, China
-
Research Site
Chongqing, 400042, China
-
Research Site
Yangzhou, 225001, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
Villejuif, 94805, France
-
Research Site
George Town, 10450, Malaysia
-
Research Site
Johor Bahru, 81100, Malaysia
-
Research Site
Kuantan, 25100, Malaysia
-
Research Site
Kuching, 93586, Malaysia
-
Research Site
Szczecin, 70-419, Poland
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Donggu, 44033, South Korea
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
Conditions
Explore the condition pages connected to this study.